Compare Nuwellis Inc (NUWE) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs BlackRock TCP Capital Corp — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while BlackRock TCP Capital Corp trades at $4.04 (market cap $337.71M). The key difference: BlackRock TCP Capital Corp is far larger — about 153.5× Nuwellis Inc's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and BlackRock TCP Capital Corp for 88 Days on average.
| NUWE | TCPC | |
|---|---|---|
Market Cap | $2.20M | $337.71M |
Volume | 121,544 | 436,109 |
Sector | Health | Financials |
52-Week High | $146.65 | $6.20 |
52-Week Low | $0.68 | $3.13 |
Typical Hold Time | 26 Days | 88 Days |
Enterprise Value | -$1.52M | $1.09B |
Dividend Yield | — | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
TCPC trades at $3.94, down 1.25% today, with a bearish technical signal and mixed fundamentals. The company reported negative revenue and net income for 2025, though recent earnings beat expectations. A strategic portfolio sale of $523 million aims to reduce leverage, while analyst sentiment leans cautious with 69% hold ratings. The stock shows a low P/B ratio of 0.61, suggesting potential undervaluation relative to assets.
Outlook remains challenged by persistent negative profitability and revenue trends, with projected declines through 2026. The strategic review and dividend yield near 4.3% offer some upside, but risks include class action lawsuits and execution uncertainty. Investors should weigh the discount to book value against fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
